These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21602694)

  • 1. Elevated CD8 counts during HAART are associated with HIV virologic treatment failure.
    Krantz EM; Hullsiek KH; Okulicz JF; Weintrob AC; Agan BK; Crum-Cianflone NF; Ganesan A; Ferguson TM; Hale BR;
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):396-403. PubMed ID: 21602694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated CD8 T-cell counts and virological failure in HIV-infected patients after combination antiretroviral therapy.
    Ku NS; Jiamsakul A; Ng OT; Yunihastuti E; Cuong DD; Lee MP; Sim BLH; Phanuphak P; Wong WW; Kamarulzaman A; Zhang F; Pujari S; Chaiwarith R; Oka S; Mustafa M; Kumarasamy N; Van Nguyen K; Ditangco R; Kiertiburanakul S; Merati TP; Durier N; Choi JY;
    Medicine (Baltimore); 2016 Aug; 95(32):e4570. PubMed ID: 27512885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure.
    Uy J; Armon C; Buchacz K; Wood K; Brooks JT;
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):450-3. PubMed ID: 19474757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.
    Rudy BJ; Lindsey JC; Flynn PM; Bosch RJ; Wilson CM; Hughes ME; Douglas SD;
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):213-21. PubMed ID: 16545007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru].
    Alave J; Paz J; González E; Campos M; Rodríguez M; Willig J; Echevarría J
    Rev Chilena Infectol; 2013 Feb; 30(1):42-8. PubMed ID: 23450408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing the Association Between Alcohol and HIV Virologic Failure in a Military Cohort on Antiretroviral Therapy.
    Deiss RG; Mesner O; Agan BK; Ganesan A; Okulicz JF; Bavaro M; Lalani T; O'Bryan TA; Bebu I; Macalino GE
    Alcohol Clin Exp Res; 2016 Mar; 40(3):529-35. PubMed ID: 26916712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.
    Saracino A; Lorenzini P; Lo Caputo S; Girardi E; Castelli F; Bonfanti P; Rusconi S; Caramello P; Abrescia N; Mussini C; Monno L; d'Arminio Monforte A;
    Clin Microbiol Infect; 2016 Mar; 22(3):288.e1-8. PubMed ID: 26551839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of first-line antiretroviral therapy failure in HIV-infected Thai children and adolescents.
    Bunupuradah T; Sricharoenchai S; Hansudewechakul R; Klinbuayaem V; Teeraananchai S; Wittawatmongkol O; Akarathum N; Prasithsirikul W; Ananworanich J;
    Pediatr Infect Dis J; 2015 Mar; 34(3):e58-62. PubMed ID: 25478649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
    Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
    AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.
    Joya C; Won SH; Schofield C; Lalani T; Maves RC; Kronmann K; Deiss R; Okulicz J; Agan BK; Ganesan A
    Clin Infect Dis; 2019 Nov; 69(12):2145-2152. PubMed ID: 30785191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
    Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa.
    Datay MI; Boulle A; Mant D; Yudkin P
    J Acquir Immune Defic Syndr; 2010 Aug; 54(5):489-95. PubMed ID: 20395870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of suspending HAART in selected patients with controlled HIV replication.
    Jacobs B; Neil N; Aboulafia DM
    AIDS Patient Care STDS; 2005 Jul; 19(7):429-38. PubMed ID: 16053400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.